Prediction Markets Under Fire 16 States Launch Legal Actions Against Platforms US Payrolls Surge Past Expectations in April Yet Underlying Weaknesses Persist JPMorgans 2025 Summer Reading List for Wealthy Clients Features AI Leadership and Lemons Fed Dissenters Explain No Votes Disagreement Over Signaling Potential Rate Cut Movado Group Inc Files Quarterly Report 10Q Reveals Latest Financial Performance Los Angeles Dodgers 182 Million Loss Highlights Financial Risks in MLB Pitcher Recovery Cycles SSC Technologies Q1 2026 Earnings Slight EPS Beat Amid Steady Operations ITIC Q4 2025 Earnings Strong EPS Reported Amid Market Uncertainty Gladstone Investment Corporation 4875 Notes due 2028 GAINZ Q1 2026 Earnings EPS Miss While Notes Trade Flat Stabilis Solutions Q1 2026 Earnings A Sharp Earnings Miss as Losses Widen Advantage Solutions Inc ADV Q1 2026 Earnings Staggering EPS Beat Drives Massive Stock Surge YJ Q3 2024 Earnings Significant EPS Miss Triggers Stock Decline Chain Bridge Bancorp CBNA Slides 177 as Stock Tests Key Support Levels Brookfield Infrastructure Preferred Shares BIPJ Slip Slightly as YieldSeeking Investors Weigh Market Dynamics Autonomix Medical AMIX Shows Subtle Weakness at 042 as Support and Resistance Tighten Plumas Bancorp PLBC Dips Slightly Remains in Established Trading Range Gabelli Utility Trust GUT Edges Higher in Quiet Session Oura Health Files Confidentially for IPO Signaling Growth in Wearable Tech Market ENVA Q1 2026 Earnings EPS Beats Estimates Stock Rises 139 Trilogy Metals TMQ Edges Higher as Stock Consolidates Near Support MOMO Q4 2025 Earnings EPS Misses Estimates by Wide Margin Stock Declines York Water Company YORW Q1 2026 Earnings EPS Beats Estimates Amid Steady Utility Operations PGNY Q1 2026 Earnings EPS Falls Short of Estimates Despite Modest Stock Gain ETOR Q1 2026 Earnings Earnings Beat Expectations with 2342 Surprise RxSight Inc Q1 2026 Earnings EPS Misses Estimates Amid Operational Headwinds MAA Q1 2026 Earnings Strong EPS Surprise of 31 Amid Mixed Revenue Visibility SGMT Q1 2026 Earnings EPS Beat as Clinical Development Costs Tighten